HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says
Executive Summary
Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow
You may also be interested in...
Medco’s Health Reform Formula: Efficiencies Outweigh Access, Payment
Medco is promoting a health care reform agenda that emphasizes cost savings from more efficient and effective care instead of focusing on who pays the bills
Senate Blocks Medicare Drug Price Negotiation Bill From Floor Vote
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: